← Back to Search

Antiviral

Valacyclovir for Gum Disease

Phase < 1

Recruiting

Led By Mike Sabeti, DDS

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be systemically healthy, Class I dental category.

Involved teeth must have periodontal disease detectible by periodontal examination.

Must not have

External or internal tooth resorption

Tooth perforation from the pulp cavity through the tip of the root exposing the tissue to material in the oral cavity

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Summary

This trial will test if a herpesvirus drug can help stop the progression of severe gum disease in adults.

Who is the study for?

This trial is for adults with severe gum disease, evidenced by deep periodontal pockets and specific x-ray findings. Participants must be in good overall health and not smoke heavily. Pregnant or nursing women, those allergic to valacyclovir, under 18s, individuals with kidney issues or immune-altering conditions/medications are excluded.Check my eligibility

What is being tested?

The study tests if Valacyclovir (Valtrex), an anti-herpesvirus medication, can halt the progression of severe gum disease. It's a double-blind trial where patients are randomly assigned to either the Valacyclovir group or a placebo control group.See study design

What are the potential side effects?

Potential side effects of Valacyclovir may include headache, nausea, stomach pain, vomiting and dizziness. Rarely it might cause more serious reactions like changes in mental state or kidney problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am generally healthy and have no major dental issues.

Select...

My teeth have gum disease confirmed by a dental exam.

Select...

I have deep gum disease with significant bone loss.

Select...

I am generally healthy and have no major dental issues.

Select...

My teeth have gum disease confirmed by a dental exam.

Select...

I have deep gum disease with significant bone loss.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have tooth decay from inside or on the surface.

Select...

I have a tooth with a hole from the inside to the tip exposing it to my mouth.

Select...

I am younger than 18 years old.

Select...

I have kidney problems or my kidneys don’t work well.

Select...

I need dialysis for my kidney condition.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Clinical attachment level

Periodontal pocket depth

gingival bleeding on probing

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: valacyclovir groupExperimental Treatment1 Intervention

Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) ("Valacyclovir" group).

Group II: Control groupActive Control1 Intervention

Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days ("Control" group).

0 / 11Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,528 Previous Clinical Trials

15,242,592 Total Patients Enrolled

Mike Sabeti, DDSPrincipal InvestigatorUniversity of California, San Francisco

2 Previous Clinical Trials

250 Total Patients Enrolled

Media Library

Valacyclovir (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT05712343 — Phase < 1

Gum Disease Research Study Groups: valacyclovir group, Control group

Gum Disease Clinical Trial 2023: Valacyclovir Highlights & Side Effects. Trial Name: NCT05712343 — Phase < 1

Valacyclovir (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05712343 — Phase < 1

~18 spots leftby Jul 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.